Cost-Utility Comparison of Bevacizumab and Aflibercept in the Treatment of Central or Hemiretinal Vein Occlusion in the SCORE2 Trial
05/2023
Journal Article
Authors:
Kymes, S. M.;
Oden, N. L.;
VanVeldhuisen, P. C.;
Scott, I. U.;
Ip, M. S.;
Blodi, B. A.;
King, J.;
Score Investigator Group
Volume:
141
Pagination:
554-561
Issue:
6
Journal:
JAMA Ophthalmol
PMID:
37166820
URL:
https://www.ncbi.nlm.nih.gov/pubmed/37166820
DOI:
10.1001/jamaophthalmol.2023.1463
Keywords:
Humans Bevacizumab/therapeutic use *Retinal Vein Occlusion/complications/diagnosis/drug therapy *Macular Edema/etiology/complications Angiogenesis Inhibitors/therapeutic use Receptors, Vascular Endothelial Growth Factor/therapeutic use
Recombinant Fusion Proteins/therapeutic use Intravitreal Injections
Abstract:
IMPORTANCE: Retinal vein occlusion is the second most common retinal vascular disease. Bevacizumab was demonstrated in the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) to be noninferior to aflibercept with respect to visual acuity in study participants with macular edema due to central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO) following 6 months of therapy. In this study, the cost-utility of bevacizumab vs aflibercept for treatment of CRVO is evaluated. OBJECTIVE: To investigate the relative cost-effectiveness of bevacizumab vs aflibercept for treatment of macular edema associated with CRVO or HRVO. DESIGN, SETTING, AND PARTICIPANTS: This economic evaluation study used a microsimulation cohort of patients with clinical and demographic characteristics similar to those of SCORE2 participants and a Markov process. Parameters were estimated and validated using a split-sample approach of the SCORE2 population. The simulated cohort included 5000 patients who were evaluated 100 times, each with a different set of characteristics randomly selected based on the SCORE2 trial. SCORE2 data were collected from September 2014 October 2019, and data were analyzed from October 2019 to July 2021. INTERVENTIONS: Bevacizumab (followed by aflibercept among patients with a protocol-defined poor or marginal response to bevacizumab at month 6) vs aflibercept (followed by a dexamethasone implant among patients with a protocol-defined poor or marginal response to aflibercept at month 6). MAIN OUTCOMES AND MEASURES: Incremental cost-utility ratio. RESULTS: The simulation demonstrated that patients treated with aflibercept will have an expected cost $18 127 greater than those treated with bevacizumab in the year following initiation. When coupled with the lack of clinical superiority over bevacizumab (ie, patients treated with bevacizumab had a gain over aflibercept in visual acuity letter score of 4 in the treated eye and 2 in the fellow eye), these results demonstrate that first-line treatment with bevacizumab dominated aflibercept in the simulated cohort of SCORE2 participants. At current price levels, aflibercept would be considered the preferred cost-effective option only if treatment restored the patient to nearly perfect health. CONCLUSIONS AND RELEVANCE: While there will be some patients with CRVO-associated or HRVO-associated macular edema who will benefit from first-line treatment with aflibercept rather than bevacizumab, given the minimal differences in visual acuity outcomes and large cost differences for bevacizumab vs aflibercept, first-line treatment with bevacizumab is cost-effective for this condition.
